Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Number To Know…10

Executive Summary

10 minutes is the time it takes to prep the non-surgical, ingestible Elipse gastric balloon for obesity treatment. Elipse is developed by Allurion Technologies, which just bagged $19m in new funding.

10 minutes is all it takes to fill Allurion Technologies' Elipse gastric balloon with fluid as part of an in-office, non-surgical treatment for obesity. The balloon is delivered as a capsule attached to a catheter; the patient swallows the capsule and it degrades in the stomach. The balloon is then filled with 550ml of fluid via the catheter, after which the catheter is removed through the mouth. Allurion raised $19m in January in a private equity round involving 45 investors. It is planning to raise up to $27m in total. Elipse was CE marked in December 2015.

To read Medtech Insight's article on advances in minimally invasive obesity management technologies, click here.

Meddevicetracker subscribers can access a profile of Allurion Technologies and a clinical trial analysis of Elipse. Not a Meddevicetracker subscriber, click here to request your free demo.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts